Rituximab News
Mabthera Approved for Use in Rheumatoid Arthritis in Europe
Unique mode of action brings new treatment option to rheumatoid arthritis suffers with an inadequate response to current biologic therapies.
Rituxan® Effective in Treatment of Splenic Marginal Zone Lymphoma and Marginal Zone Lymphoma
According to the results of a study published in the journal Cancer, the targeted therapy Rituxan® (rituximab) appears to be effective in the treatment of two relatively uncommon types of non-Hodgkin’s lymphoma—splenic marginal...
Rituxan® Effective in Chronic Graft-Versus-Host Disease
According to an early online publication in the journal Blood, the agent Rituxan® (rituximab) appears effective and well tolerated in the treatment of chronic graft-versus-host-disease.
Rituximab Effective in Treating Chronic Graft-Versus-Host Disease
Dana-Farber researchers found that rituximab reduced the severity of chronic graft-versus-host disease (GVHD) in 70 percent of the study participants. Chronic GVHD is a potentially life-threatening complication of donor bone...